Drug Profile
Uteroferrin
Latest Information Update: 29 Aug 2002
Price :
$50
*
At a glance
- Originator Pepgen Corporation
- Class
- Mechanism of Action Colony stimulating factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaemia; Leucopenia
Most Recent Events
- 19 Apr 1999 New profile
- 19 Apr 1999 Preclinical development for Anaemia in USA (Unknown route)
- 19 Apr 1999 Preclinical development for Leucopenia in USA (Unknown route)